Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer

C Carvalho, R Glynne-Jones - The Lancet Oncology, 2017 - thelancet.com
For patients with high-risk stage II or stage III colon cancer, adjuvant chemotherapy with
fluoropyrimidine monotherapy reduces the risk of recurrence and death by approximately 20 …
被引用次数：110 相关文章

[引用][C] Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer

C Carvalho, R Glynne-Jones - The Lancet Oncology, 2017 - cir.nii.ac.jp
Challenges behind proving efficacy of adjuvant chemotherapy after preoperative
chemoradiation for rectal cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer.

C Carvalho, R Glynne-Jones - The Lancet. Oncology, 2017 - europepmc.org
For patients with high-risk stage II or stage III colon cancer, adjuvant chemotherapy with
fluoropyrimidine monotherapy reduces the risk of recurrence and death by approximately 20 …

Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer

C Carvalho, R Glynne-Jones - The Lancet Oncology, 2017 - Elsevier
For patients with high-risk stage II or stage III colon cancer, adjuvant chemotherapy with
fluoropyrimidine monotherapy reduces the risk of recurrence and death by approximately 20 …

Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer

C Carvalho, R Glynne-Jones - The Lancet. Oncology, 2017 - pubmed.ncbi.nlm.nih.gov
For patients with high-risk stage II or stage III colon cancer, adjuvant chemotherapy with
fluoropyrimidine monotherapy reduces the risk of recurrence and death by approximately 20 …